Greenland Mines Engages Tetra Tech and GeoSim for S-K 1300 Resource Update at Sarfartoq Rare Earth Project

Greenland Mines Ltd (NASDAQ: GRML) announced the engagement of Tetra Tech Canada Inc. and GeoSim Services Inc. to prepare an updated SEC S-K 1300-compliant mineral resource estimate for its Sarfartoq neodymium-praseodymium (Nd-Pr) rare earth project in southwest Greenland. The updated resource estimate, expected to be substantially completed this summer, will incorporate historical NI 43-101 resource work along with drilling and technical studies completed by Neo Performance Materials between 2023 and 2025. This estimate is intended to support an updated preliminary economic assessment and future development studies.

GeoSim, led by Ronald G. Simpson, P.Geo., has been appointed as the qualified person for the resource estimate, providing continuity from earlier Sarfartoq resource and economic studies completed in 2011 and 2012. Tetra Tech will provide engineering, mine planning and metallurgical support, including optimization studies evaluating open-pit, underground and hybrid development scenarios. Greenland Mines also reappointed WSP Danmark A/S to continue environmental baseline work at the project as the company advances Sarfartoq, which it believes is distinguished by a strong neodymium-praseodymium component and strategic relevance to Western rare earth supply chains.

The Sarfartoq project is part of Greenland Mines' broader strategy to build a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities. The company is also advancing its North Atlantic Critical Metals Corridor vision, which links Greenland resources with allied downstream jurisdictions and industrial infrastructure. Greenland Mines operates two divisions: Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of a previously announced transaction, the Sarfartoq Nd-Pr project; and Biotech, including Klotho’s KLTO‑202 primary indication for ALS.

Investors can view the full press release at https://ibn.fm/eIurP and find the latest news and updates relating to GRML in the company’s newsroom at https://ibn.fm/GRML.